Thalidomide: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Thalidomide |FDA_approval=Yes (for leprosy and multiple myeloma) |used_for=Investigational use in various cancers due to antiangiogenic and immunomodulatory properties |clinical_trial_phase=Ongoing optimization of thalidomide analogues |common_side_effects=Deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, teratogenicity |OS_with=Not specified; ongoing studies for cancer-specific outcomes |PFS_with=Not specifi...") |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 9: | Line 9: | ||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|notes=Recent advances in thalidomide-related compounds target anticancer efficacy with reduced side effects. These developments suggest thalidomide analogues could become a promising therapeutic alternative for cancer treatment, enhancing the drug's applicability beyond its current FDA-approved uses. Continued research aims to refine these compounds to maximize benefits and minimize risks. | |notes=Recent advances in thalidomide-related compounds target anticancer efficacy with reduced side effects. These developments suggest thalidomide analogues could become a promising therapeutic alternative for cancer treatment, enhancing the drug's applicability beyond its current FDA-approved uses. Continued research aims to refine these compounds to maximize benefits and minimize risks. | ||
| | |treatment_category=Repurposed Drugs | ||
|links= | |links= | ||
|toxicity_level=4 | |||
|toxicity_explanation=Thalidomide, although it has shown promise in treating various cancers, has a high level of toxicity due to side effects such as deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, and teratogenicity (risks to a developing fetus). As such, it's rated as 4 out of 5, with 5 being the most toxic. Keep in mind that these effects may vary from person to person, so it is important to discuss the risks and benefits with your healthcare provider. | |||
}} | }} | ||
Latest revision as of 10:24, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | Thalidomide |
| FDA Approval | Yes (for leprosy and multiple myeloma) |
| Used for | Investigational use in various cancers due to antiangiogenic and immunomodulatory properties |
| Clinical Trial Phase | Ongoing optimization of thalidomide analogues |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, teratogenicity |
| OS without | Not specified |
| OS with | Not specified; ongoing studies for cancer-specific outcomes |
| PFS without | Not specified |
| PFS with | Not specified; research focuses on enhancing therapeutic profiles while minimizing toxicity |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 4 |
| Toxicity Explanation | Thalidomide, although it has shown promise in treating various cancers, has a high level of toxicity due to side effects such as deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, and teratogenicity (risks to a developing fetus). As such, it's rated as 4 out of 5, with 5 being the most toxic. Keep in mind that these effects may vary from person to person, so it is important to discuss the risks and benefits with your healthcare provider. |
Notes: Recent advances in thalidomide-related compounds target anticancer efficacy with reduced side effects. These developments suggest thalidomide analogues could become a promising therapeutic alternative for cancer treatment, enhancing the drug's applicability beyond its current FDA-approved uses. Continued research aims to refine these compounds to maximize benefits and minimize risks.
From Ben Williams Book: Not specified
Loading comments...
